Nivolumab Effective in Advanced Non-Squamous NSCLC

Video

In this video, Dr. Paz-Ares discusses a phase III study that showed that nivolumab improved survival and response rates in previously treated patients with metastatic non-squamous non-small-cell lung cancer (NSCLC).

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected

      In this video, Luis Paz-Ares, MD, discusses a phase III study that showed that nivolumab improved survival and response rates in previously treated patients with metastatic non-squamous non-small-cell lung cancer (NSCLC), with the largest improvement seen in PD-L1-positive patients.

      The data were presented at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting.

      Recent Videos
      In a CancerNetwork® YouTube video, Cornelia Tischmacher, a mother of twins from Germany, outlined her receipt of double lung transplantation.
      Highlighting the DREAM Program for Late-Stage Lung Cancer Treatment
      Ongoing ctDNA analysis may elucidate outcomes associated with divarasib plus migoprotafib for those with KRAS G12C–positive NSCLC.
      Divarasib Combo Appears “Promising” in Pretreated KRAS G12C+ NSCLC
      Future of HER2-Directed Tumor-Agnostic Therapies
      Future of HER2-Directed Tumor-Agnostic Therapies
      Influence of DESTINY-PanTumor02 Trials on Trastuzumab Deruxtecan Usage
      Influence of DESTINY-PanTumor02 Trials on Trastuzumab Deruxtecan Usage
      Review of Current Landscape of HER2-Directed Tumor-Agnostic Therapies
      Review of Current Landscape of HER2-Directed Tumor-Agnostic Therapies
      Updates and Clinical Implications of DESTINY-Lung02 and DESTINY-Lung03 Trials
      Updates and Clinical Implications of DESTINY-Lung02 and DESTINY-Lung03 Trials
      HER2 Key Differences and Current Approaches to Biomarker Testing
      HER2 Key Differences and Current Approaches to Biomarker Testing
      Introduction to HER2-Directed Tumor-Agnostic Approaches
      Introduction to HER2-Directed Tumor-Agnostic Approaches
      The FirstLook liquid biopsy, when used as an adjunct to low-dose CT, may help to address the unmet need of low lung cancer screening utilization.
      Lung Cancer Home Health Screening Tools May Aid in Triaging LDCT+ Patients
      An 80% sensitivity for lung cancer was observed with the liquid biopsy, with high sensitivity observed for early-stage disease, as well.
      Cell-Free DNA Assay Achieves High Negative Predicative Value in Lung Cancer
      Related Content
      Twice-Daily Hyperfractionated Thoracic Radiotherapy Effective at 60 Gy in SCLC

      Twice-Daily Hyperfractionated Thoracic Radiotherapy Effective at 60 Gy in SCLC

      Tim Cortese
      June 6th 2025
      Article

      A phase 2 trial demonstrated a median overall survival of 43.5 months at 60 Gy compared with 22.5 months at 45 Gy in patients with limited-stage SCLC.

      Georgios Evangelou, MD, MSc, speaks to the potential utility of neoadjuvant capecitabine/temozolomide in well-differentiated atypical carcinoids.

      Exploring the Value of Preoperative CAPTEM in Atypical Lung NETs

      Georgios Evangelou, MD, MSc
      September 16th 2024
      Podcast

      Georgios Evangelou, MD, MSc, speaks to the potential utility of neoadjuvant capecitabine/temozolomide in well-differentiated atypical carcinoids.

      Six or More Cycles of Chemo Prolong Survival With Atezolizumab in ES-SCLC

      Six or More Cycles of Chemo Prolong Survival With Atezolizumab in ES-SCLC

      Tim Cortese
      June 4th 2025
      Article

      The median OS was 18.5 months in those who received 6 or more cycles of induction chemotherapy vs 13.1 months in those who did not.

      Rian M. Hasson Charles, MD, MPH, FACS, discusses advances in equitable lung cancer screening and her experiences as a woman in thoracic oncology.

      Achieving Health Equity in Lung Cancer Surgery

      Rian M. Hasson Charles, MD, MPH, FACS
      April 1st 2024
      Podcast

      Rian M. Hasson Charles, MD, MPH, FACS, discusses advances in equitable lung cancer screening and her experiences as a woman in thoracic oncology.

      Neoadjuvant Alectinib Effective, Tolerable in Late-Stage ALK-Positive NSCLC

      Neoadjuvant Alectinib Effective, Tolerable in Late-Stage ALK-Positive NSCLC

      Tim Cortese
      June 2nd 2025
      Article

      Neoadjuvant alectinib met the primary end point with a major pathologic response rate of 42% in patients with potentially resectable stage III NSCLC.

      3 Things You Should Know About the Multimodal Treatment of SCLC

      3 Things You Should Know About the Multimodal Treatment of SCLC

      Lauren Averett Byers, MD;Percy Lee, MD, FASTRO;Erminia Massarelli, MD, PhD, MS
      May 19th 2025
      Article

      Here are 3 things you should know about the multimodal treatment of patients with SCLC.